2025-04-01 2026-03-31 false Capium Accounts Production 1.1 11983548 2025-04-01 2026-03-31 11983548 bus:AbridgedAccounts 2025-04-01 2026-03-31 11983548 bus:Micro-entities 2025-04-01 2026-03-31 11983548 bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 11983548 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 11983548 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 11983548 2025-04-01 2026-03-31 11983548 2026-03-31 11983548 bus:RegisteredOffice 2025-04-01 2026-03-31 11983548 core:WithinOneYear 2026-03-31 11983548 core:AfterOneYear 2026-03-31 11983548 1 2025-04-01 2026-03-31 11983548 bus:Director1 2025-04-01 2026-03-31 11983548 bus:Director1 2026-03-31 11983548 bus:Director1 2024-04-01 2025-03-31 11983548 bus:Director2 2025-04-01 2026-03-31 11983548 bus:Director2 2026-03-31 11983548 bus:Director2 2024-04-01 2025-03-31 11983548 2024-04-01 11983548 bus:LeadAgentIfApplicable 2025-04-01 2026-03-31 11983548 2024-04-01 2025-03-31 11983548 2025-03-31 11983548 core:WithinOneYear 2025-03-31 11983548 core:AfterOneYear 2025-03-31 11983548 bus:EntityAccountantsOrAuditors 2024-04-01 2025-03-31 11983548 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 11983548 bus:OrdinaryShareClass1 2026-03-31 11983548 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 11983548 bus:OrdinaryShareClass1 2025-03-31 11983548 core:CostValuation core:Non-currentFinancialInstruments 2026-03-31 11983548 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 11983548 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2026-03-31 11983548 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 11983548 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 11983548 core:Non-currentFinancialInstruments 2026-03-31 11983548 core:Non-currentFinancialInstruments 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 11983548
England and Wales
REN PHARMA SCIENCES LTD
Abridged Accounts
Period of accounts Start date: 01 April 2025 End date: 31 March 2026

REN PHARMA SCIENCES LTD Contents Page For the year ended 31 March 2026
Statement of Financial Position | 1

REN PHARMA SCIENCES LTD Statement of Financial Position As at 31 March 2026
|  | 2026 |  | 2025
--- | --- | --- | --- | ---
|  | £ | £ |  | £ | £
Current assets |  | 43,357 |  |  | 91,010 |
Creditors: amount falling due within one year |  | (29,403) |  |  | (76,181) |
Net current assets |  |  | 13,954 |  |  | 14,829
Total assets less current liabilities |  |  | 13,954 |  |  | 14,829
Creditors: amount falling due after more than one year |  |  | (11,669) |  |  | (14,033)
Provisions for liabilities |  |  | (262) |  |  | (549)
Net assets |  |  | 2,023 |  |  | 247
Capital and reserves |  |  | 2,023 |  |  | 247
NOTES TO THE ACCOUNTS General Information REN PHARMA SCIENCES LTD is a private company, limited by shares, registered in England and Wales, registration number 11983548, registration address Office Gold, Building 7, Floor 5, 566 Chiswick High Road, Chiswick Business Park,, London, England, W4 5YG. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention. The financial statements are prepared in sterling which is the functional currency of the company. Going concern basis The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Foreign currencies Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the statement of financial position date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All foreign exchange differences are included to the income statement. Provisions Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.
2. | Average number of employees Average number of employees during the year was 6 (2025 : 7).
For the year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Directors' responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies. The members have agreed to the preparation of abridged accounts. The financial statements were approved by the board of directors on 20 August 2026 and were signed on its behalf by:
-------------------------------- Naresh Renikindi Director
1